AZD9793 Trial for Liver Cancer
Phase 1/2
304
about 3.3 years
18+
6 sites in CA, MD, MO +2
What this study is about
This trial is testing AZD9793, a new treatment, in people with advanced or metastatic liver cancer. The goal is to see if AZD9793 is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive AZD9793 Intravenous (IV) monotherapy
- 2.Receive AZD9793 Subcutaneous (SC) monotherapy)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
infusion, injection
Primary: Objective Response Rate (ORR) [Part B Dose Expansion only], The number of AEs leading to discontinuation of AZD9793, The number of patients with adverse events, The number of patients with adverse events of special interest, The number of patients with dose-limiting toxicity (DLT), as defined in the protocol [Part A Dose Escalation only], The number of patients with serious adverse events
Secondary: Best overall response (BOR), Disease Control Rate (DCR) at 12 weeks, Durable response rate (DRR), Duration of response (DoR), Objective Response Rate (ORR) [Part A Dose Escalation only], Overall Survival (OS) [Dose expansion only], Pharmacokinetics of AZD9793: Area Under the concentration-time curve (AUC), Pharmacokinetics of AZD9793: Clearance